Commercial
  
  
  
  
  
  
  
  
  
  
MPattachmentdataPub
8d777768-65bb-4b72-8681-5bc568ba8782.aspx
  
08.00.62mAbatacept(Orencia®)forInjectionforIntravenousUse08.00.62mPharmacy (08)Abatacept (Orencia®) for Injection for Intravenous Use8d777768-65bb-4b72-8681-5bc568ba87823542Abatacept (Orencia®) for Injection for Intravenous Use08.00.62
{"3543": {"Id":3543,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5693,"PolicyAttachmentPageName":"b5270336-b546-46c9-a742-ffbf76936bc7"},}
9b891878-088a-46b3-87eb-d2032e21e161.aspx
  
12.00.01fAcupuncture(Independence)12.00.01fMiscellaneous (12)Acupuncture (Independence)9b891878-088a-46b3-87eb-d2032e21e1613177Acupuncture (Independence)12.00.01
{"3178": {"Id":3178,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":5410,"PolicyAttachmentPageName":"0c7269c3-4107-4e68-a3d6-0913e0b02dcd"},}
151d34b6-4e58-416b-b105-5282cd83c5f4.aspx
  
12.00.01gAcupuncture(Independence)12.00.01gMiscellaneous (12)Acupuncture (Independence)151d34b6-4e58-416b-b105-5282cd83c5f43625Acupuncture (Independence)12.00.01
{"3626": {"Id":3626,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":5770,"PolicyAttachmentPageName":"162a73bf-e53e-4008-9b6f-f3b142e31096"},}
a26ef448-30db-43ac-94c2-e6d4b2be4b3a.aspx
  
12.04.04aAcuteCareFacilityInpatientTransfers12.04.04aMiscellaneous (12)Acute Care Facility Inpatient Transfersa26ef448-30db-43ac-94c2-e6d4b2be4b3a3272Acute Care Facility Inpatient Transfers12.04.04
b1b70e6b-f0a4-4e8d-a402-c16710ec6422.aspx
  
08.01.11fAdo-TrastuzumabEmtansine(Kadcyla®)08.01.11fPharmacy (08)Ado-Trastuzumab Emtansine (Kadcyla®)b1b70e6b-f0a4-4e8d-a402-c16710ec64222880Ado-Trastuzumab Emtansine (Kadcyla®)08.01.11
{"2881": {"Id":2881,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes and Narratives","MPPolicyAttachmentInternalSourceId":4967,"PolicyAttachmentPageName":"93337778-48af-4f3e-8a67-96c5f917cbb1"},}
119a4599-f16d-4baf-b41b-f1bce92d9fcc.aspx
  
08.00.69cAgalsidasebeta(Fabrazyme®)08.00.69cPharmacy (08)Agalsidase beta (Fabrazyme®)119a4599-f16d-4baf-b41b-f1bce92d9fcc3510Agalsidase beta (Fabrazyme®)08.00.69
225d3101-03b1-4bcf-bbb9-96b94e93d897.aspx
  
12.04.03cAirAmbulanceServices12.04.03cMiscellaneous (12)Air Ambulance Services225d3101-03b1-4bcf-bbb9-96b94e93d8973340Air Ambulance Services12.04.03
73aa91d4-6dd1-4f04-aca2-d73e96227091.aspx
  
08.01.22dAlemtuzumab(Lemtrada®)08.01.22dPharmacy (08)Alemtuzumab (Lemtrada®)73aa91d4-6dd1-4f04-aca2-d73e962270913349Alemtuzumab (Lemtrada®)08.01.22
50caa1df-13dc-4e47-9fb2-e9b82bdf4f34.aspx
  
08.00.72iAlglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®)08.00.72iPharmacy (08)Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® )50caa1df-13dc-4e47-9fb2-e9b82bdf4f343676Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® )08.00.72
ed39b1c3-6d7a-468f-a34f-d38ae5a9c7b9.aspx
  
07.00.21jAllergyImmunotherapy07.00.21jMedicine (07)Allergy Immunotherapyed39b1c3-6d7a-468f-a34f-d38ae5a9c7b93158Allergy Immunotherapy07.00.21
50885de3-59ab-43a6-9222-a0a4e00c9908.aspx
  
06.02.29dAlloMap™MolecularExpressionTestingforHeartTransplantRejection(IndependenceAdministrators)06.02.29dPathology and Laboratory (06)AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)50885de3-59ab-43a6-9222-a0a4e00c99083169AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)06.02.29
5382f61c-2acd-4417-831b-1daf8729bdbc.aspx
  
08.00.91eAlpha1-AntitrypsinTherapy(e.g.,Prolastin-C®,AralastNP®,Glassia®,Zemaira®)08.00.91ePharmacy (08)Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)5382f61c-2acd-4417-831b-1daf8729bdbc2892Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)08.00.91
982f9c86-2f4c-42b8-a516-0bae6a045edc.aspx
  
00.01.52nAlwaysBundledProcedureCodes00.01.52nAdministrative (00)Always Bundled Procedure Codes982f9c86-2f4c-42b8-a516-0bae6a045edc3690Always Bundled Procedure Codes00.01.52
{"3691": {"Id":3691,"MPAttachmentLetter":"A","Title":"Always Bundled Procedures (Indicator B)","MPPolicyAttachmentInternalSourceId":5718,"PolicyAttachmentPageName":"8be182b4-5251-4bf3-b894-7f759ea55632"},"3692": {"Id":3692,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":5719,"PolicyAttachmentPageName":"68b8744c-9df1-4f00-bea7-54f6056050fb"},"3693": {"Id":3693,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":5720,"PolicyAttachmentPageName":"4b718a83-786b-48a0-8745-8f871c53cd81"},}
fadd0242-f323-49fe-8ca7-2112b67a09c4.aspx
  
07.02.09gAmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)Devices07.02.09gMedicine (07)Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devicesfadd0242-f323-49fe-8ca7-2112b67a09c43006Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices07.02.09
87e16786-6329-4dac-b7f8-9ab74d3edb7f.aspx
  
07.02.21gAmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)Monitoring07.02.21gMedicine (07)Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring87e16786-6329-4dac-b7f8-9ab74d3edb7f3537Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring07.02.21
365f2a39-981c-447c-afd0-31715fcb046a.aspx
  
08.01.82Anifrolumab-fnia(Saphnelo™)08.01.82Pharmacy (08)Anifrolumab-fnia (Saphnelo™)365f2a39-981c-447c-afd0-31715fcb046a3677Anifrolumab-fnia (Saphnelo™)08.01.82
cf9faf96-487d-47c2-bd76-bc70fd056a33.aspx
  
05.00.39rAnkle-Foot/Knee-Ankle-FootOrthoses05.00.39rDME (05)Ankle-Foot/Knee-Ankle-Foot Orthosescf9faf96-487d-47c2-bd76-bc70fd056a333409Ankle-Foot/Knee-Ankle-Foot Orthoses05.00.39
{"3410": {"Id":3410,"MPAttachmentLetter":"A","Title":"HCPCS Codes","MPPolicyAttachmentInternalSourceId":5437,"PolicyAttachmentPageName":"5f6e2c31-1bcc-46e6-9727-fc05459b2621"},}
36aee0bb-d271-4e94-8256-eafdfce45397.aspx
  
06.03.04nApheresisTherapy06.03.04nPathology and Laboratory (06)Apheresis Therapy36aee0bb-d271-4e94-8256-eafdfce453972774Apheresis Therapy06.03.04
877c1fd6-b369-4fc9-8864-59f82b761dc2.aspx
  
11.08.05gApplicationandRemovalofTattoos11.08.05gSurgery (11)Application and Removal of Tattoos877c1fd6-b369-4fc9-8864-59f82b761dc22642Application and Removal of Tattoos11.08.05
202addae-a8d3-482f-b7b2-e3af034fa355.aspx
  
08.01.41cAprepitant(Cinvanti™),FosaprepitantDimeglumine(Emend®),Granisetron(Sustol®),andRolapitant(Varubi®)08.01.41cPharmacy (08)Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)202addae-a8d3-482f-b7b2-e3af034fa3553470Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)08.01.41
{"3471": {"Id":3471,"MPAttachmentLetter":"A","Title":"Risk of Emesis Without Prophylaxis: Intravenous and Oral Antineoplastic Agents","MPPolicyAttachmentInternalSourceId":5660,"PolicyAttachmentPageName":"00411fd3-0b49-4077-9c80-e7d25e6698cf"},}
f4ad855b-1bf8-4318-9dfb-398610d6aa5d.aspx
  
11.05.16iAqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucoma11.05.16iSurgery (11)Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucomaf4ad855b-1bf8-4318-9dfb-398610d6aa5d3312Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma11.05.16
{"3313": {"Id":3313,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":5521,"PolicyAttachmentPageName":"ce13f43a-df56-4a6c-b295-d70cd335fca5"},}
b0e984df-bd5e-4e0d-85e6-c2a0b64cb49d.aspx
  
11.14.19pArtificialIntervertebralCervicalDiscInsertion(IndependenceAdministrators)11.14.19pSurgery (11)Artificial Intervertebral Cervical Disc Insertion (Independence Administrators)b0e984df-bd5e-4e0d-85e6-c2a0b64cb49d3704Artificial Intervertebral Cervical  Disc Insertion (Independence Administrators)11.14.19
5d023597-bc1e-40ec-8616-4e86387f03a2.aspx
  
11.15.31ArtificialIntervertebralLumbarDiscInsertion11.15.31Surgery (11)Artificial Intervertebral Lumbar Disc Insertion5d023597-bc1e-40ec-8616-4e86387f03a23666Artificial Intervertebral Lumbar Disc Insertion11.15.31
0cb612eb-b2de-4e38-8972-5383f6a5e515.aspx
  
08.01.35dAsparaginaseErwiniaChrysanthemi(Erwinaze®),asparaginaseerwiniachrysanthemi(recombinant)-rywn(Rylaze™)08.01.35dPharmacy (08)Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™)0cb612eb-b2de-4e38-8972-5383f6a5e5153529Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™)08.01.35
9181dc9f-7943-4cc9-a854-5ec1c5357691.aspx
  
06.02.27lAssaysofGeneticExpressioninTumorTissueforBreastCancerPrognosis(IndependenceAdministrators)06.02.27lPathology and Laboratory (06)Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)9181dc9f-7943-4cc9-a854-5ec1c53576913168Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)06.02.27
964f2d08-cb46-4737-8a74-39b81deb6f6a.aspx
  
07.10.06iAssistedReproductiveTechnologyforInfertilityandOocyteCryopreservation07.10.06iMedicine (07)Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation964f2d08-cb46-4737-8a74-39b81deb6f6a2824Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation07.10.06
718ec7af-0c6e-4a4e-8f6d-883490f0c164.aspx
  
08.01.69aAtezolizumab(Tecentriq®)08.01.69aPharmacy (08)Atezolizumab (Tecentriq®)718ec7af-0c6e-4a4e-8f6d-883490f0c1643508Atezolizumab (Tecentriq®)08.01.69
{"3509": {"Id":3509,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":5655,"PolicyAttachmentPageName":"914e332c-7a2c-46dc-91cd-1cde4190ec52"},}
70726fcf-404b-4ff9-9280-ac452ac48c19.aspx
  
11.14.06jAutologousChondrocyteImplantation(ACI)andOtherCell-basedTreatmentsofFocalArticularCartilageLesions(IndependenceAdministrators)11.14.06jSurgery (11)Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)70726fcf-404b-4ff9-9280-ac452ac48c192932Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)11.14.06
6e37e5d6-bbaf-48fa-a6c3-063563373e0a.aspx
  
05.00.29lAutomaticExternalCardioverterDefibrillators(WearableandNonwearable)05.00.29lDME (05)Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)6e37e5d6-bbaf-48fa-a6c3-063563373e0a3492Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)05.00.29
{"3493": {"Id":3493,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":5694,"PolicyAttachmentPageName":"6cb3f087-d8e1-46f2-bb16-e4c0efccf069"},"3494": {"Id":3494,"MPAttachmentLetter":"A","Title":"ICD-10 Codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":5695,"PolicyAttachmentPageName":"663a7b01-481b-406b-a86b-acc389b6356f"},}
4efbfdc0-b5ec-43df-9116-dd957dace7cf.aspx
  
07.03.23dAutonomicNervousSystemTesting07.03.23dMedicine (07)Autonomic Nervous System Testing4efbfdc0-b5ec-43df-9116-dd957dace7cf3326Autonomic Nervous System Testing07.03.23
7e0e42f8-cf2c-4eb6-a9d8-4b172c1df27a.aspx
  
08.01.64Avelumab(Bavencio®)08.01.64Pharmacy (08)Avelumab (Bavencio®)7e0e42f8-cf2c-4eb6-a9d8-4b172c1df27a2451Avelumab (Bavencio®)08.01.64
{"2452": {"Id":2452,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":2486,"PolicyAttachmentPageName":"924afd68-e6b3-4c07-98e4-722d7e259554"},}
b4850e37-c01a-4c04-aef2-7d9fed86e706.aspx
  
11.16.06jBalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitis11.16.06jSurgery (11)Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitisb4850e37-c01a-4c04-aef2-7d9fed86e7062695Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis11.16.06
e2e22104-ada2-4d84-9c71-c600f1ea170e.aspx
  
11.03.02tBariatricSurgery11.03.02tSurgery (11)Bariatric Surgerye2e22104-ada2-4d84-9c71-c600f1ea170e2791Bariatric Surgery11.03.02
{"2792": {"Id":2792,"MPAttachmentLetter":"A","Title":"Body Mass Index (BMI) Charts","MPPolicyAttachmentInternalSourceId":4907,"PolicyAttachmentPageName":"292a20ba-ec48-442c-a624-40100880cb31"},"2793": {"Id":2793,"MPAttachmentLetter":"B","Title":"Tanner Staging System Criteria for Adolescents","MPPolicyAttachmentInternalSourceId":4908,"PolicyAttachmentPageName":"1b6da816-a2b6-4583-807a-5430c89f8392"},"2794": {"Id":2794,"MPAttachmentLetter":"C","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":4909,"PolicyAttachmentPageName":"b9184a36-7491-498e-aac9-ed1933abf92b"},}
bde34a1a-c1f2-4778-b78a-72050d24e484.aspx
  
08.01.70bBelantamabmafodotin-blmf(Blenrep)08.01.70bPharmacy (08)Belantamab mafodotin-blmf (Blenrep)bde34a1a-c1f2-4778-b78a-72050d24e4843176Belantamab mafodotin-blmf (Blenrep)08.01.70
a538b471-570c-403b-9114-cc764e9fba6a.aspx
  
08.00.99dBelimumab(Benlysta®)forIntravenousUse08.00.99dPharmacy (08)Belimumab (Benlysta®) for Intravenous Usea538b471-570c-403b-9114-cc764e9fba6a3036Belimumab (Benlysta®) for Intravenous Use08.00.99
e5743575-3866-4edc-bdc2-d245636c2623.aspx
  
08.00.66pBevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUse08.00.66pPharmacy (08)Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Usee5743575-3866-4edc-bdc2-d245636c26233552Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use08.00.66
{"3553": {"Id":3553,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":5779,"PolicyAttachmentPageName":"ac3aa4c9-d963-45d8-8266-8a9f48e65f6e"},}
44d1f93e-e431-4e85-a65f-99ebd167ae49.aspx
  
00.10.39nBillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampus00.10.39nAdministrative (00)Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus44d1f93e-e431-4e85-a65f-99ebd167ae492901Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus00.10.39
{"2902": {"Id":2902,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus","MPPolicyAttachmentInternalSourceId":5191,"PolicyAttachmentPageName":"4d997fc7-79b5-47d4-b004-59a1ff458993"},}
7467b7be-328a-4664-89ab-13b4c0859839.aspx
  
00.10.38aBillingRequirementsforMultipleBirthsforProfessionalProviders00.10.38aAdministrative (00)Billing Requirements for Multiple Births for Professional Providers7467b7be-328a-4664-89ab-13b4c08598393051Billing Requirements for Multiple Births for Professional Providers00.10.38
{"3052": {"Id":3052,"MPAttachmentLetter":"A","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ROUTINE OBSTETRIC (GLOBALE MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5340,"PolicyAttachmentPageName":"d157b661-7eea-46ea-ab0f-b6ec2bd15a87"},"3053": {"Id":3053,"MPAttachmentLetter":"B","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ANETEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5341,"PolicyAttachmentPageName":"5d22c25e-12c7-42e4-a127-e50b59895309"},"3054": {"Id":3054,"MPAttachmentLetter":"C","Title":"CODING SCENARIOS FOR REPORTING HIGH-ORDER MULTIPLE (TRIPLETS, QUADRUPLETS, ETC) BIRTHS WHEN ROUTINE OBSTETRIC (GLOBAL MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5342,"PolicyAttachmentPageName":"d0a0d176-67d6-4d41-9e52-2cbec1ebff3d"},"3055": {"Id":3055,"MPAttachmentLetter":"D","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF HIGH-ORDER MULTIPLES WHEN ANTEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5343,"PolicyAttachmentPageName":"74d58125-3d75-4d7b-8d89-cbaebd03cc03"},}
c953a697-6789-487c-85c5-74cc02b327f3.aspx
  
07.00.01jBiofeedbackTherapy07.00.01jMedicine (07)Biofeedback Therapyc953a697-6789-487c-85c5-74cc02b327f33669Biofeedback Therapy07.00.01
6b56ce1e-6818-41bb-9061-330aebb8ecf5.aspx
  
07.06.03bBioimpedencefortheDetectionofLymphedema07.06.03bMedicine (07)Bioimpedence for the Detection of Lymphedema6b56ce1e-6818-41bb-9061-330aebb8ecf53321Bioimpedence for the Detection of Lymphedema07.06.03
05af1ff1-9439-4274-90cd-c00835000c0e.aspx
  
11.05.02jBlepharoplasty,RepairofBlepharoptosis,RepairofBrowPtosis,andCanthoplasty/Canthopexy11.05.02jSurgery (11)Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy05af1ff1-9439-4274-90cd-c00835000c0e2975Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy11.05.02
{"2976": {"Id":2976,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5006,"PolicyAttachmentPageName":"4cca31c1-c0b9-45fc-bfdb-e773e1b7116a"},}
2d06cc9f-7fee-4974-8d3b-5354317cf365.aspx
  
08.01.21dBlinatumomab(Blincyto®)08.01.21dPharmacy (08)Blinatumomab (Blincyto®)2d06cc9f-7fee-4974-8d3b-5354317cf3653287Blinatumomab (Blincyto®)08.01.21
92e12e9d-2a7b-499b-bbe2-cbb276bc17ba.aspx
  
11.01.06eBone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAids11.01.06eSurgery (11)Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids92e12e9d-2a7b-499b-bbe2-cbb276bc17ba2702Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids11.01.06
76a3c9fb-280f-49e8-b8ce-7d213e0ec49f.aspx
  
09.00.04kBoneMineralDensity(BMD)Testing09.00.04kRadiology (09)Bone Mineral Density (BMD) Testing76a3c9fb-280f-49e8-b8ce-7d213e0ec49f3239Bone Mineral Density (BMD) Testing09.00.04
baa812b2-43e6-4cff-82b5-9592a674f59e.aspx
  
08.00.73mBortezomib(BortezomibforInjection,Velcade®)08.00.73mPharmacy (08)Bortezomib (Bortezomib for Injection, Velcade®)baa812b2-43e6-4cff-82b5-9592a674f59e3150Bortezomib (Bortezomib for Injection, Velcade®)08.00.73
f3a2fbd3-38cb-431f-8734-441b29bf1dfa.aspx
  
08.00.26xBotulinumToxinAgents08.00.26xPharmacy (08)Botulinum Toxin Agentsf3a2fbd3-38cb-431f-8734-441b29bf1dfa3171Botulinum Toxin Agents08.00.26
{"3172": {"Id":3172,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":5156,"PolicyAttachmentPageName":"b99590fc-80da-417b-b8a5-4da094ad7d28"},}
4cb3894b-2c2b-4737-a0c4-1ba6c6a65167.aspx
  
09.00.10zBrachytherapyandAcceleratedWholeBreastIrradiationusingThree-DimensionalConformationRadiationTherapy09.00.10zRadiology (09)Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy4cb3894b-2c2b-4737-a0c4-1ba6c6a651673041Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy09.00.10
28248bd2-5b32-49ca-87b0-e1cfda1abbc7.aspx
  
05.00.76dBreastPumps05.00.76dDME (05)Breast Pumps28248bd2-5b32-49ca-87b0-e1cfda1abbc72720Breast Pumps05.00.76
87590db1-6d5c-4464-88c7-ad4cf440f953.aspx
  
08.01.13fBrentuximabVedotin(Adcetris®)08.01.13fPharmacy (08)Brentuximab Vedotin (Adcetris®)87590db1-6d5c-4464-88c7-ad4cf440f9533550Brentuximab Vedotin (Adcetris®)08.01.13
{"3551": {"Id":3551,"MPAttachmentLetter":"A","Title":"ICD CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5777,"PolicyAttachmentPageName":"a3d243de-946f-412f-812a-07d699556559"},}
85256AA800623D7A852585A4005899AC.aspx
  
11.16.07bBronchial ThermoplastySurgery (11)Bronchial Thermoplasty85256AA800623D7A852585A4005899AC1791Bronchial Thermoplasty11.16.07
d7f202d9-ab28-404f-adf1-0798651bfeb6.aspx
  
08.01.49bBurosumab-twza(Crysvita®)08.01.49bPharmacy (08)Burosumab-twza (Crysvita®)d7f202d9-ab28-404f-adf1-0798651bfeb63034Burosumab-twza (Crysvita®)08.01.49
38d30b81-d6e8-498c-bccd-3c3f2baa02a4.aspx
  
08.01.51aCanakinumab(Ilaris®)08.01.51aMiscellaneous (12)Canakinumab (Ilaris®)38d30b81-d6e8-498c-bccd-3c3f2baa02a43000Canakinumab (Ilaris®)08.01.51
70f913cb-a2d4-40de-ba99-3b2938c110b7.aspx
  
10.01.01nCardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)Programs10.01.01nRehabilitation Services (10)Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs70f913cb-a2d4-40de-ba99-3b2938c110b73672Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs10.01.01
{"3673": {"Id":3673,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5729,"PolicyAttachmentPageName":"9edc8373-3d61-4d0c-9158-b0716b073418"},}
8e339ceb-45a8-4a58-a802-6e0d86f524a5.aspx
  
00.01.59hCareManagementandCarePlanningServices00.01.59hAdministrative (00)Care Management and Care Planning Services8e339ceb-45a8-4a58-a802-6e0d86f524a52893Care Management and Care Planning Services00.01.59
26a9c1aa-7bed-41e2-a468-178e8e009f8c.aspx
  
08.01.05gCarfilzomib(Kyprolis®)08.01.05gPharmacy (08)Carfilzomib (Kyprolis®)26a9c1aa-7bed-41e2-a468-178e8e009f8c2645Carfilzomib (Kyprolis®)08.01.05
9a58b2c2-ac51-4f36-b633-45311f346cea.aspx
  
00.10.15dCastandSplintApplicationsandAssociatedSupplies00.10.15dAdministrative (00)Cast and Splint Applications and Associated Supplies9a58b2c2-ac51-4f36-b633-45311f346cea2782Cast and Splint Applications and Associated Supplies00.10.15
{"2783": {"Id":2783,"MPAttachmentLetter":"A","Title":"Procedure Codes Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":4979,"PolicyAttachmentPageName":"0e216c08-2117-49fb-87c3-6ff39b233cd3"},}
a9523e11-70dc-40cb-9b0d-1dd63928d745.aspx
  
11.01.07eCataractSurgery11.01.07eSurgery (11)Cataract Surgerya9523e11-70dc-40cb-9b0d-1dd63928d7453233Cataract Surgery11.01.07
{"3234": {"Id":3234,"MPAttachmentLetter":"A","Title":"ICD 10 codes for policy 11.01.07d, Cataract Surgery","MPPolicyAttachmentInternalSourceId":5477,"PolicyAttachmentPageName":"0c14c509-e3b3-4c66-8fee-360d2972c969"},}
974db979-b925-49bc-967a-582689ec10ef.aspx
  
11.02.06mCatheterAblationofCardiacArrhythmias11.02.06mSurgery (11)Catheter Ablation of Cardiac Arrhythmias974db979-b925-49bc-967a-582689ec10ef3523Catheter Ablation of Cardiac Arrhythmias11.02.06
85256AA800623D7A8525857A004FE849.aspx
  
08.01.66Cemiplimab-rwlc (LIBTAYO®)Pharmacy (08)Cemiplimab-rwlc (LIBTAYO®)85256AA800623D7A8525857A004FE8492398Cemiplimab-rwlc (LIBTAYO®)08.01.66
d0bf9cac-5008-4f9d-a225-598e388f07d8.aspx
  
08.01.39cCerliponasealfa(Brineura®)08.01.39cPharmacy (08)Cerliponase alfa (Brineura®)d0bf9cac-5008-4f9d-a225-598e388f07d83188Cerliponase alfa (Brineura®)08.01.39
a11f7cc3-9d42-42f0-8f28-deb4b0380548.aspx
  
05.00.61gCervicalTractionDevicesforIn-homeUse05.00.61gDME (05)Cervical Traction Devices for In-home Usea11f7cc3-9d42-42f0-8f28-deb4b03805482640Cervical Traction Devices for In-home Use05.00.61
cdbc995f-3e19-494b-8ec1-a6cffbb1b055.aspx
  
08.00.67mCetuximab(Erbitux®)08.00.67mPharmacy (08)Cetuximab (Erbitux®)cdbc995f-3e19-494b-8ec1-a6cffbb1b0553500Cetuximab (Erbitux®)08.00.67
{"3501": {"Id":3501,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":5391,"PolicyAttachmentPageName":"0782f068-f334-4ef3-8575-fcdd56442627"},"3502": {"Id":3502,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":5392,"PolicyAttachmentPageName":"adcb6987-3065-4605-a151-afd058941acf"},}
c9c846c6-7feb-44a7-bccc-e1a79d2f0ddf.aspx
  
11.08.08gChemicalPeels11.08.08gSurgery (11)Chemical Peelsc9c846c6-7feb-44a7-bccc-e1a79d2f0ddf3516Chemical Peels11.08.08
55b36986-1cad-421b-a19e-232e52669b03.aspx
  
08.01.43iChimericAntigenReceptor(CAR)Therapy08.01.43iPharmacy (08)Chimeric Antigen Receptor (CAR) Therapy55b36986-1cad-421b-a19e-232e52669b033647Chimeric Antigen Receptor (CAR) Therapy08.01.43
{"3648": {"Id":3648,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5892,"PolicyAttachmentPageName":"90d4c734-e617-4328-9c2c-6697dd50bd5a"},}
c042c02a-0451-49be-a2c5-a513ea157169.aspx
  
10.02.02jChiropracticSpinalandExtraspinalManipulationTherapy10.02.02jRehabilitation Services (10)Chiropractic Spinal and Extraspinal Manipulation Therapyc042c02a-0451-49be-a2c5-a513ea1571693280Chiropractic Spinal and Extraspinal Manipulation Therapy10.02.02
465ad1f4-30bc-45ac-8114-468e0f652a26.aspx
  
08.00.92acCoagulationFactors08.00.92acPharmacy (08)Coagulation Factors 465ad1f4-30bc-45ac-8114-468e0f652a262736Coagulation Factors 08.00.92
7a3c932b-cb41-4962-910e-cdc4585c93bb.aspx
  
06.02.54bCobalamin(VitaminB12),FolicAcid,andHomocysteineTesting06.02.54bPathology and Laboratory (06)Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing7a3c932b-cb41-4962-910e-cdc4585c93bb3634Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing06.02.54
{"3635": {"Id":3635,"MPAttachmentLetter":"A","Title":"MEDICALLY NECESSARY ICD 10 CODES FOR COBALAMIN (VITAMIN B12) AND/OR FOLIC ACID TESTING (CPT CODES 82607, 82608, 82746, AND 82747)","MPPolicyAttachmentInternalSourceId":5890,"PolicyAttachmentPageName":"bf89c4a8-2b16-4888-ac1b-452d1dc9b489"},}
52e574a3-d754-4e64-ae47-a5d0662891ef.aspx
  
11.01.02pCochlearImplant11.01.02pSurgery (11)Cochlear Implant52e574a3-d754-4e64-ae47-a5d0662891ef3123Cochlear Implant11.01.02
e099201b-9a35-4d40-a33e-66396302d48e.aspx
  
08.01.71Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo™)08.01.71Pharmacy (08)Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™)e099201b-9a35-4d40-a33e-66396302d48e3458Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™)08.01.71
f7fbacdf-3a64-436d-99a7-7750aa0ab7d1.aspx
  
11.03.12tColorectalCancerScreening11.03.12tSurgery (11)Colorectal Cancer Screeningf7fbacdf-3a64-436d-99a7-7750aa0ab7d13357Colorectal Cancer Screening11.03.12
B55889244594F1F085258574005DA579.aspx
  
12.00.03gComplementary and Integrative Health ServicesMiscellaneous (12)Complementary and Integrative Health ServicesB55889244594F1F085258574005DA5792104Complementary and Integrative Health Services12.00.03
74d20bbd-cd53-4d56-b994-33ea919b217c.aspx
  
07.06.01bCompleteDecongestiveTherapy(CDT)07.06.01bMedicine (07)Complete Decongestive Therapy (CDT)74d20bbd-cd53-4d56-b994-33ea919b217c3330Complete Decongestive Therapy (CDT)07.06.01
cfc67080-f181-438d-9190-d1df58f6bc1d.aspx
  
11.14.30CompositeTissueAllotransplantationoftheHand(s)andFace11.14.30Surgery (11)Composite Tissue Allotransplantation of the Hand(s) and Facecfc67080-f181-438d-9190-d1df58f6bc1d3197Composite Tissue Allotransplantation of the Hand(s) and Face11.14.30
edddd201-1bf2-479f-9f86-1fd2713538d5.aspx
  
05.00.37fCompressionGarments05.00.37fDME (05)Compression Garmentsedddd201-1bf2-479f-9f86-1fd2713538d53195Compression Garments05.00.37
f076fe82-4422-4ecd-b854-e6d0a1f17257.aspx
  
09.00.42cComputer-AidedDetection(CAD)SystemforUsewithChestRadiographs09.00.42cRadiology (09)Computer-Aided Detection (CAD) System for Use with Chest Radiographsf076fe82-4422-4ecd-b854-e6d0a1f172573524Computer-Aided Detection (CAD) System for Use with Chest Radiographs09.00.42
997a85b5-16c6-4037-9e9a-30ef7a8f47c8.aspx
  
11.14.17eComputer-assistedMusculoskeletalSurgicalNavigationalOrthopedicProcedure11.14.17eSurgery (11)Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure997a85b5-16c6-4037-9e9a-30ef7a8f47c83199Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure11.14.17
F3BA7DB0E980312B8525854B005EE64C.aspx
  
00.01.69Consultation ServicesAdministrative (00)Consultation ServicesF3BA7DB0E980312B8525854B005EE64C2172Consultation Services00.01.69
e5b5cfbb-d456-4bfb-8870-5aab910c343f.aspx
  
07.13.11kContactLensesfortheTreatmentofPersistent(Corneal)EpithelialDefects07.13.11kMedicine (07)Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defectse5b5cfbb-d456-4bfb-8870-5aab910c343f3581Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects07.13.11
{"3582": {"Id":3582,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5783,"PolicyAttachmentPageName":"e4eeff60-d4b9-4c77-a78b-54e723650c5c"},}
486b7833-e733-47e1-a5a2-1fb22d353084.aspx
  
09.00.11eContrastAgentsUsedinConjunctionwithEchocardiography09.00.11eRadiology (09)Contrast Agents Used in Conjunction with Echocardiography486b7833-e733-47e1-a5a2-1fb22d3530843091Contrast Agents Used in Conjunction with Echocardiography09.00.11
985d887d-5350-4c1c-ba1d-4dd28827fdc5.aspx
  
07.13.07kCornealPachymetryUsingUltrasound07.13.07kMedicine (07)Corneal Pachymetry Using Ultrasound985d887d-5350-4c1c-ba1d-4dd28827fdc52651Corneal Pachymetry Using Ultrasound07.13.07
{"2652": {"Id":2652,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":4969,"PolicyAttachmentPageName":"eb3a5e1b-6833-42ae-88c0-4bc890ca50cb"},}
70aeb740-4e46-455e-abef-c6d9421a64e8.aspx
  
12.01.03aCosmeticProcedures12.01.03aMiscellaneous (12)Cosmetic Procedures70aeb740-4e46-455e-abef-c6d9421a64e83329Cosmetic Procedures12.01.03
fe8d8f3e-2421-4eca-88de-1d339c70efa1.aspx
  
08.01.08fCoverageofAnticancerPrescriptionOralandInjectableDrugsandBiologicsandSupportiveAgents08.01.08fPharmacy (08)Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agentsfe8d8f3e-2421-4eca-88de-1d339c70efa13649Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents08.01.08
{}
0e5a3246-799b-4df3-bc4a-9a5c0ec82166.aspx
  
05.00.04eCoverageofMedicalDevices05.00.04eDME (05)Coverage of Medical Devices0e5a3246-799b-4df3-bc4a-9a5c0ec821663665Coverage of Medical Devices05.00.04
57d5d404-40e8-4bca-b4b5-39fe907e8b06.aspx
  
05.00.80ACranialElectrotherapyStimulation05.00.80ADME (05)Cranial Electrotherapy Stimulation57d5d404-40e8-4bca-b4b5-39fe907e8b062612Cranial Electrotherapy Stimulation05.00.80
81e6e200-2094-43e9-804d-25c02aa5f8bf.aspx
  
05.00.25iCranialRemoldingOrthoses(Helmets)05.00.25iDME (05)Cranial Remolding Orthoses (Helmets)81e6e200-2094-43e9-804d-25c02aa5f8bf2998Cranial Remolding Orthoses (Helmets)05.00.25
85256AA800623D7A852584710058EC0E.aspx
  
00.10.03jCriteria for Reimbursement of Emergency Room ServicesAdministrative (00)Criteria for Reimbursement of Emergency Room Services85256AA800623D7A852584710058EC0E2001Criteria for Reimbursement of Emergency Room Services00.10.03
f6a258a4-1a08-4ad9-aee7-39f1f23d4fb6.aspx
  
08.00.04crizanlizumab-tmca(Adakveo®)08.00.04Pharmacy (08)crizanlizumab-tmca (Adakveo®)f6a258a4-1a08-4ad9-aee7-39f1f23d4fb63175crizanlizumab-tmca (Adakveo®)08.00.04
6398d8a3-6df3-482a-8408-a2ac2e2ee22b.aspx
  
11.11.03dCryosurgicalAblationoftheProstateGland11.11.03dSurgery (11)Cryosurgical Ablation of the Prostate Gland6398d8a3-6df3-482a-8408-a2ac2e2ee22b3203Cryosurgical Ablation of the Prostate Gland11.11.03
c52b181a-c56d-458d-b762-7932fdcf8937.aspx
  
08.01.29iDaratumumab(Darzalex®),Daratumumab,andHyaluronidase-fihj(DarzalexFaspro®)08.01.29iPharmacy (08)Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®)c52b181a-c56d-458d-b762-7932fdcf89373289Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®)08.01.29
7af90fad-1979-498e-98f3-5da73f3bfad9.aspx
  
10.00.02cDayRehabilitation10.00.02cRehabilitation Services (10)Day Rehabilitation7af90fad-1979-498e-98f3-5da73f3bfad93351Day Rehabilitation10.00.02
e3eb36bf-27fc-4bb7-aff5-6392d35d8cfe.aspx
  
11.08.17kDebridementofMycoticandSymptomaticNon-MycoticHypertrophicToeNails11.08.17kSurgery (11)Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nailse3eb36bf-27fc-4bb7-aff5-6392d35d8cfe3609Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails11.08.17
{"3610": {"Id":3610,"MPAttachmentLetter":"E","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (S86.892A - Z79.01), Continued","MPPolicyAttachmentInternalSourceId":5830,"PolicyAttachmentPageName":"47c3847f-3512-4996-8ae4-d969b12de906"},"3611": {"Id":3611,"MPAttachmentLetter":"D","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (I87.099 - S86.891S), Continued","MPPolicyAttachmentInternalSourceId":5831,"PolicyAttachmentPageName":"d31c3e08-8923-4e3b-a452-c413b6846627"},"3612": {"Id":3612,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E13.3513 - I87.093), Continued","MPPolicyAttachmentInternalSourceId":5832,"PolicyAttachmentPageName":"3da31121-131b-49c8-b4b3-4c849684a0f6"},"3613": {"Id":3613,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E10.22 - E13.3512), Continued","MPPolicyAttachmentInternalSourceId":5833,"PolicyAttachmentPageName":"cf173c8f-936f-4cd4-908e-4add60b9ed31"},"3614": {"Id":3614,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (A30.0 -E10.21)","MPPolicyAttachmentInternalSourceId":5834,"PolicyAttachmentPageName":"987ca92f-46fc-43f6-8bf7-3d3a9d6b601c"},}
3ecc3555-70b4-4662-ae43-bfa5024ef24e.aspx
  
11.15.20pDeepBrainStimulation(DBS)11.15.20pSurgery (11)Deep Brain Stimulation (DBS)3ecc3555-70b4-4662-ae43-bfa5024ef24e2629Deep Brain Stimulation (DBS)11.15.20
9d08591b-5d8c-4efd-94cf-1c418e174bac.aspx
  
11.15.09pDenervationoftheSpinalNervesforChronicPain(IndependenceAdministrators)11.15.09pSurgery (11)Denervation of the Spinal Nerves for Chronic Pain (Independence Administrators)9d08591b-5d8c-4efd-94cf-1c418e174bac3549Denervation of the Spinal  Nerves for Chronic Pain (Independence Administrators)11.15.09
0f6392a1-2719-450d-980d-71109cfbbf99.aspx
  
08.00.94oDenosumab(Prolia®,Xgeva®),Romosozumab-aqqg(Evenity®)08.00.94oPharmacy (08)Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)0f6392a1-2719-450d-980d-71109cfbbf993185Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)08.00.94
{"3186": {"Id":3186,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes","MPPolicyAttachmentInternalSourceId":5349,"PolicyAttachmentPageName":"1cf1d69b-23e3-49fb-82c0-805cfc574fa9"},}
ef37cab5-6501-4d87-acad-5bf9060d23d4.aspx
  
00.03.02abDiagnosticRadiologyServicesIncludedinCapitation00.03.02abAdministrative (00)Diagnostic Radiology Services Included in Capitationef37cab5-6501-4d87-acad-5bf9060d23d42960Diagnostic Radiology Services Included in Capitation00.03.02
{"2961": {"Id":2961,"MPAttachmentLetter":"A","Title":"Diagnostic Radiology Procedure Codes Included in Capitation for Pennsylvania (PA) Health Maintenance Organization (HMO) Members","MPPolicyAttachmentInternalSourceId":5246,"PolicyAttachmentPageName":"1a071f00-e2c4-47cb-9af9-e77692b0d24c"},}
9c981601-10cc-4167-a854-9da704832694.aspx
  
00.09.01hDirectAccesstoObstetrics/Gynecology(OB/GYN)Services00.09.01hAdministrative (00)Direct Access to Obstetrics/Gynecology (OB/GYN) Services9c981601-10cc-4167-a854-9da7048326942912Direct Access to Obstetrics/Gynecology (OB/GYN) Services00.09.01
{"2913": {"Id":2913,"MPAttachmentLetter":"A","Title":"Procedure Codes for Direct Access OB/GYN","MPPolicyAttachmentInternalSourceId":5193,"PolicyAttachmentPageName":"06aff05f-ffda-49be-930f-087f93089d77"},}
dbbe3feb-80d9-4d66-bbd2-6135accf52d1.aspx
  
08.00.49eDofetilide(Tikosyn®)UseintheInpatientSetting08.00.49ePharmacy (08)Dofetilide (Tikosyn®) Use in the Inpatient Settingdbbe3feb-80d9-4d66-bbd2-6135accf52d13210Dofetilide (Tikosyn®) Use in the Inpatient Setting08.00.49
c531f106-36a2-483a-9618-1d9666179096.aspx
  
08.01.79aDostarlimab-gxly(Jemperli)08.01.79aPharmacy (08)Dostarlimab-gxly (Jemperli)c531f106-36a2-483a-9618-1d96661790963629Dostarlimab-gxly (Jemperli)08.01.79
73cccc6d-90e9-4c06-b4b7-5b1be78578a5.aspx
  
07.05.07dDrug-ElutingBeadsandBlandEmbolizationfortheTreatmentofHepaticMalignancies07.05.07dMedicine (07)Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies73cccc6d-90e9-4c06-b4b7-5b1be78578a53705Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies07.05.07
1f4283fc-5e91-48fe-a0ec-deae8a129738.aspx
  
08.01.37aDrugsUsedfortheMaintenanceTreatmentofOpioidorAlcoholUseDisorder(e.g.,NaltrexoneImplants,ProbuphineImplant,SublocadeInjection,VivitrolInjection)08.01.37aPharmacy (08)Drugs Used for the Maintenance Treatment of Opioid or Alcohol Use Disorder (e.g., Naltrexone Implants, Probuphine Implant, Sublocade Injection, Vivitrol Injection)1f4283fc-5e91-48fe-a0ec-deae8a1297383479Drugs Used for the Maintenance Treatment of Opioid or Alcohol Use Disorder (e.g., Naltrexone Implants, Probuphine Implant, Sublocade Injection, Vivitrol Injection)08.01.37
1 - 100Next